Testing ELV001 for active rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This study tests a new medication, ELV001, for people with active rheumatoid arthritis who haven't improved enough with methotrexate and a TNF inhibitor. The goal is to see if different doses of ELV001 are safe and can help reduce joint pain and swelling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had rheumatoid arthritis for at least 6 months and it is currently active (with swollen and tender joints).
- You have been taking methotrexate for at least 6 months (stable dose for at least 3 months).
- You have been on a TNF inhibitor (like etanercept, adalimumab, or infliximab) for at least 6 months and it has only partially helped.
- You have not tried more than one other biologic or targeted medication besides your current TNF inhibitor.
- You are willing to use reliable birth control during and for 90 days after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
This trial tests an experimental drug for people with rheumatoid arthritis who have not had success with other treatments. It aims to see if the drug can help reduce joint pain and swelling.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
Hear when a new Active Rheumatoid Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.